California Institute of Regenerative Medicine awards multi‑million grants to stem‑cell biotech firms

California Institute of Regenerative Medicine awards multi‑million grants to stem‑cell biotech firms The passage details public funding allocations to biotech companies but contains no allegations of misconduct, financial impropriety, or links to high‑level officials. It offers limited investigative value beyond confirming grant amounts and recipients, which are already public. Key insights: CIRM allocated $10.1 M to ViaCyte, $9.3 M to Bluebird Bio, and up to $20 M each to StemCells Inc. for separate projects.; Grants are part of CIRM’s Strategic Partnership Awards aimed at moving stem‑cell therapies toward FDA approval.; Publicly‑listed stem‑cell companies saw share price gains in 2013, partly attributed to regulatory approvals and trial data.